Anadis wins approval to initiate Phase IV oral HIV therapy study
In the study, Anadis’s BioGard will be used alone and in combination with the new Merck anti-AIDS drug Isentress (raltegravir). This investigator initiated CORAL study is sponsored by
Life sciences and technology companies supported by the Ontario Bioscience Innovation Organization’s (OBIO) Capital Access Advisory Program (CAAP) have collectively raised more than C$1bn ($704.7m) in capital.